Journal
PHARMACOGENOMICS & PERSONALIZED MEDICINE
Volume 14, Issue -, Pages 497-508Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/PGPM.S302755
Keywords
miR-195-5p; NSCLC; cisplatin; chemosensitivity; FGF2
Categories
Funding
- National Natural Science Foundation of China [81772619, 82002551]
- Clinical Trial Project of Tianjin Medical University [2017kylc006]
- Bethune Charitable Foundation [HZB-20190528-18]
Ask authors/readers for more resources
The study revealed that miR-195-5p plays a crucial role in non-small cell lung cancer and cisplatin resistance, potentially reducing resistance and enhancing chemotherapy sensitivity by targeting FGF2.
Objective: To explore the mechanism of miR-195-5p in the pathogenesis non-small cell lung cancer (NSCLC) and cisplatin resistance. Methods: The function of miR-195-5p in NSCLC and cisplatin resistance were determined by MTT, scratch assay, transwell assay, and nude mice xenograft experiments. miR-195-5p target gene was identified by dual-luciferase reporter assays and real-time PCR analysis. Results: miR-195-5p content was lower in A549/DDP than that in A549 cells, with reduced chemotherapy sensitivity and increased cell invasion and migration ability. The loss-of-function and gain-of-function assays illustrated that miR-195-5p might have increased the chemosensitivity to cisplatin in the A549/DDP cells and decreased cell migration and invasion. FGF2 is a negatively correlated action target of miR-195-5p. miR-195-5p might affect EMT by inhibiting FGF2. Overexpression of FGF2 resulted in enhanced cisplatin resistance in the cells, while miR-195-5p might have reversed this resistance. Conclusion: Overall, miR-195-5p might target FGF2 to reduce cisplatin resistance in A549/DDP cells and enhance chemosensitivity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available